Discontinuation of denosumab in men with prostate cancer.

Anne Sophie Koldkjær Sølling Torben HarsløfHelle Kongsbak BrockstedtBente Lomholt Langdahl

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)

In men with non-metastatic prostate cancer, discontinuation of DMAB after stopping ADT led to an average bone loss of 2-5%. Zoledronate prevented bone loss in men with osteopenia.

Keyphrases

bone loss
prostate cancer
radical prostatectomy
middle aged
squamous cell carcinoma
bone mineral density